TY  - JOUR
AU  - Kamusheva, Maria
AU  - Georgieva, Svetla
AU  - Lakić, Dragana
AU  - Mitov, Konstantin
AU  - Savova, Alexandra
AU  - Stoimenova, Assena
AU  - Petrova, Guenka
PY  - 2013
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1965
AB  - The aim of the present study was to analyze the cost of pharmacotherapy and quality of life of patients with cystic fibrosis (CF), Gaucher disease (GD) and chronic myeloid leukemia (CML) in Bulgaria. Data for the pharmacotherapy cost were compiled retrospectively. The second part of the study included a prospective quality-of-life survey (conducted at the Medical University Hospital "Alexandrovska" in 2010 and 2011). We estimated the average monthly pharmacotherapy costs according to data from the hospital registries. The quality-of-life survey was done through interviews based on the short form of SF-36, which measures 9 health domains. The total number of patients was 18, of which 10 were with CML, 5 with cystic fibrosis and 3 with Gaucher disease. The average age of the male and female patients with CML was 49.1 years and 48.3 years, respectively; 25 and 24 years in the group with GD, respectively; and 29.5 and 35.3 years in CF group, respectively. No statistical difference between the average monthly pharmacotherapy costs for the observed period was revealed In all patients the quality of life was below the maximum possible value, which is equal to 100 points. The lowest values for the different indicators of quality of life were observed in the CF patients, most likely due to the chronic progression of this particular rare disease. The average range of quality of life for this group was 53.75. We found a statistical correlation between the pharmacotherapy costs and the quality of life. The Spearman correlation analysis revealed a correlation between the drug therapy costs and some quality-of-life indicators only in the patients with CIVIL. The correlation between the pharmacotherapy costs and physiological functions in patients with CIVIL was positive, i.e. higher costs improved this indicator The pharmacotherapy costs were high, the average values for the three groups of patients being: BGN 9221.61 for 2010 and BGN 8254.64 for January March 2011 for patients with CF, BGN 32954.08 for those with GD, and BGN 6389.38 for 2010 and BGN 6591.19 for the second period for the CML patients. The quality of life was significantly reduced for the observed patients: the average value for quality of life were 53.75, 65.03 and 67, respectively, from a maximum of 100.
PB  - Diagnosis Press Ltd, Sofia
T2  - Biotechnology & Biotechnological Equipment
T1  - A health-related quality of life and pharmacotherapy costs study for patients with cystic fybrosis, gaucher disease and chronic myeloid leukemia in Bulgaria
VL  - 27
IS  - 3
SP  - 3896
EP  - 3900
DO  - 10.5504/BBEQ.2013.0029
ER  - 

@article{
author = "Kamusheva, Maria and Georgieva, Svetla and Lakić, Dragana and Mitov, Konstantin and Savova, Alexandra and Stoimenova, Assena and Petrova, Guenka",
year = "2013",
abstract = "The aim of the present study was to analyze the cost of pharmacotherapy and quality of life of patients with cystic fibrosis (CF), Gaucher disease (GD) and chronic myeloid leukemia (CML) in Bulgaria. Data for the pharmacotherapy cost were compiled retrospectively. The second part of the study included a prospective quality-of-life survey (conducted at the Medical University Hospital "Alexandrovska" in 2010 and 2011). We estimated the average monthly pharmacotherapy costs according to data from the hospital registries. The quality-of-life survey was done through interviews based on the short form of SF-36, which measures 9 health domains. The total number of patients was 18, of which 10 were with CML, 5 with cystic fibrosis and 3 with Gaucher disease. The average age of the male and female patients with CML was 49.1 years and 48.3 years, respectively; 25 and 24 years in the group with GD, respectively; and 29.5 and 35.3 years in CF group, respectively. No statistical difference between the average monthly pharmacotherapy costs for the observed period was revealed In all patients the quality of life was below the maximum possible value, which is equal to 100 points. The lowest values for the different indicators of quality of life were observed in the CF patients, most likely due to the chronic progression of this particular rare disease. The average range of quality of life for this group was 53.75. We found a statistical correlation between the pharmacotherapy costs and the quality of life. The Spearman correlation analysis revealed a correlation between the drug therapy costs and some quality-of-life indicators only in the patients with CIVIL. The correlation between the pharmacotherapy costs and physiological functions in patients with CIVIL was positive, i.e. higher costs improved this indicator The pharmacotherapy costs were high, the average values for the three groups of patients being: BGN 9221.61 for 2010 and BGN 8254.64 for January March 2011 for patients with CF, BGN 32954.08 for those with GD, and BGN 6389.38 for 2010 and BGN 6591.19 for the second period for the CML patients. The quality of life was significantly reduced for the observed patients: the average value for quality of life were 53.75, 65.03 and 67, respectively, from a maximum of 100.",
publisher = "Diagnosis Press Ltd, Sofia",
journal = "Biotechnology & Biotechnological Equipment",
title = "A health-related quality of life and pharmacotherapy costs study for patients with cystic fybrosis, gaucher disease and chronic myeloid leukemia in Bulgaria",
volume = "27",
number = "3",
pages = "3896-3900",
doi = "10.5504/BBEQ.2013.0029"
}

Kamusheva, M., Georgieva, S., Lakić, D., Mitov, K., Savova, A., Stoimenova, A.,& Petrova, G.. (2013). A health-related quality of life and pharmacotherapy costs study for patients with cystic fybrosis, gaucher disease and chronic myeloid leukemia in Bulgaria. in Biotechnology & Biotechnological Equipment
Diagnosis Press Ltd, Sofia., 27(3), 3896-3900.
https://doi.org/10.5504/BBEQ.2013.0029

Kamusheva M, Georgieva S, Lakić D, Mitov K, Savova A, Stoimenova A, Petrova G. A health-related quality of life and pharmacotherapy costs study for patients with cystic fybrosis, gaucher disease and chronic myeloid leukemia in Bulgaria. in Biotechnology & Biotechnological Equipment. 2013;27(3):3896-3900.
doi:10.5504/BBEQ.2013.0029 .

Kamusheva, Maria, Georgieva, Svetla, Lakić, Dragana, Mitov, Konstantin, Savova, Alexandra, Stoimenova, Assena, Petrova, Guenka, "A health-related quality of life and pharmacotherapy costs study for patients with cystic fybrosis, gaucher disease and chronic myeloid leukemia in Bulgaria" in Biotechnology & Biotechnological Equipment, 27, no. 3 (2013):3896-3900,
https://doi.org/10.5504/BBEQ.2013.0029 . .

TY  - JOUR
AU  - Georgieva, Svetla
AU  - Kamusheva, Maria
AU  - Lakić, Dragana
AU  - Mitov, Konstantin
AU  - Savova, Alexandra
AU  - Petrova, Guenka
PY  - 2012
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1729
AB  - The aim of the present study was to analyze the pharmacotherapy cost and quality of life of patents after kidney transplantation compared to those with chronic kidney disease in Bulgaria. This retrospective pharmacotherapy cost study and prospective health related quality of life (QoL) study was performed during 2010 - 2011 at the biggest Sofia hospital serving all transplant patients. The cost of pharmacotherapy was analyzed after reviewing patients' records. The health related quality of life was evaluated with the multi-attributable questionnaire SF-36, which measures 9 health domains. Forty-two percent of the patients with chronic kidney disease, and 26% of those with kidney transplant were female. The average age of the transplanted patients was 39.7 for male patients and 42.2 for female ones, while in the group suffering from chronic kidney disease the average male age was 48.3 and that of female patients, 51.2. No statistically significant difference was observed among the mean monthly cost of therapy per patient during the two-year period. The QoL was with lower values in the role limitations domain for patients with chronic kidney diseases and this difference was statistically significant. We found a correlation among the mean cost of pharmacotherapy and mean QoL in both groups of patients. In the group of patients with kidney transplantation the place of living and general health state were positively correlated. The cost of pharmacotherapy and the health state in comparison with the previous year were also positively correlated. This is the first Bulgarian study of the quality of life of kidney transplant patients. It shows that the SF-36 could be successfully used in this group of patients as well as for comparison with the QoL of patients with chronic kidney disease.
PB  - Diagnosis Press Ltd, Sofia
T2  - Biotechnology & Biotechnological Equipment
T1  - The health related quality of life for kidney transplant patients in Bulgaria - A pilot study
VL  - 26
IS  - 3
SP  - 3062
EP  - 3065
DO  - 10.5504/BBEQ.2012.0005
ER  - 

@article{
author = "Georgieva, Svetla and Kamusheva, Maria and Lakić, Dragana and Mitov, Konstantin and Savova, Alexandra and Petrova, Guenka",
year = "2012",
abstract = "The aim of the present study was to analyze the pharmacotherapy cost and quality of life of patents after kidney transplantation compared to those with chronic kidney disease in Bulgaria. This retrospective pharmacotherapy cost study and prospective health related quality of life (QoL) study was performed during 2010 - 2011 at the biggest Sofia hospital serving all transplant patients. The cost of pharmacotherapy was analyzed after reviewing patients' records. The health related quality of life was evaluated with the multi-attributable questionnaire SF-36, which measures 9 health domains. Forty-two percent of the patients with chronic kidney disease, and 26% of those with kidney transplant were female. The average age of the transplanted patients was 39.7 for male patients and 42.2 for female ones, while in the group suffering from chronic kidney disease the average male age was 48.3 and that of female patients, 51.2. No statistically significant difference was observed among the mean monthly cost of therapy per patient during the two-year period. The QoL was with lower values in the role limitations domain for patients with chronic kidney diseases and this difference was statistically significant. We found a correlation among the mean cost of pharmacotherapy and mean QoL in both groups of patients. In the group of patients with kidney transplantation the place of living and general health state were positively correlated. The cost of pharmacotherapy and the health state in comparison with the previous year were also positively correlated. This is the first Bulgarian study of the quality of life of kidney transplant patients. It shows that the SF-36 could be successfully used in this group of patients as well as for comparison with the QoL of patients with chronic kidney disease.",
publisher = "Diagnosis Press Ltd, Sofia",
journal = "Biotechnology & Biotechnological Equipment",
title = "The health related quality of life for kidney transplant patients in Bulgaria - A pilot study",
volume = "26",
number = "3",
pages = "3062-3065",
doi = "10.5504/BBEQ.2012.0005"
}

Georgieva, S., Kamusheva, M., Lakić, D., Mitov, K., Savova, A.,& Petrova, G.. (2012). The health related quality of life for kidney transplant patients in Bulgaria - A pilot study. in Biotechnology & Biotechnological Equipment
Diagnosis Press Ltd, Sofia., 26(3), 3062-3065.
https://doi.org/10.5504/BBEQ.2012.0005

Georgieva S, Kamusheva M, Lakić D, Mitov K, Savova A, Petrova G. The health related quality of life for kidney transplant patients in Bulgaria - A pilot study. in Biotechnology & Biotechnological Equipment. 2012;26(3):3062-3065.
doi:10.5504/BBEQ.2012.0005 .

Georgieva, Svetla, Kamusheva, Maria, Lakić, Dragana, Mitov, Konstantin, Savova, Alexandra, Petrova, Guenka, "The health related quality of life for kidney transplant patients in Bulgaria - A pilot study" in Biotechnology & Biotechnological Equipment, 26, no. 3 (2012):3062-3065,
https://doi.org/10.5504/BBEQ.2012.0005 . .